VALZOREY
DEAD

Serial Number

97086744

Owner

Bristol-Myers Squibb Company

Attorney

Marilyn F. Kelly

Filing Date

Oct 21, 2021

Add to watchlist:

No watchlists yet
View on USPTO

VALZOREY Trademark

Serial Number: 97086744

VALZOREY is a trademark filed by Bristol-Myers Squibb Company on October 21, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Bristol-Myers Squibb Company (57 trademarks)

Route 206 & Province Line Road
Princeton, NJ 08543

Entity Type: 03

Trademark Details

Filing Date

October 21, 2021

Registration Date

Not Registered

Published for Opposition

February 28, 2023

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jun 1, 2026 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jun 1, 2026 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 18, 2026 EXRA
SOU EXTENSION 5 GRANTED
Feb 17, 2026 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 11, 2026 AITU
SOU TEAS EXTENSION RECEIVED
Sep 24, 2025 EEXT
SOU EXTENSION 5 FILED
Sep 23, 2025 EXT5
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 9, 2025 EXRA
SOU EXTENSION 4 GRANTED
Apr 9, 2025 EX4G
SOU EXTENSION 4 FILED
Apr 9, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
Apr 9, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 23, 2024 EXRA
SOU EXTENSION 3 GRANTED
Oct 23, 2024 EX3G
SOU EXTENSION 3 FILED
Oct 23, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Oct 23, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 15, 2024 EXRA
SOU EXTENSION 2 GRANTED
Mar 14, 2024 EX2G
SOU EXTENSION 2 FILED
Mar 14, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Mar 14, 2024 EEXT
ASSIGNED TO EXAMINER
Oct 23, 2023 DOCK
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 13, 2023 EXRA
SOU EXTENSION 1 GRANTED
Oct 11, 2023 EX1G
SOU EXTENSION 1 FILED
Oct 11, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Oct 11, 2023 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 2, 2023 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 2, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 2, 2023 COAR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 25, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 28, 2023 NPUB
PUBLISHED FOR OPPOSITION
Feb 28, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 8, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 25, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 16, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 15, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 15, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 27, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jun 27, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jun 27, 2022 CNRT
ASSIGNED TO EXAMINER
Jun 26, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 7, 2021 NWOS
NEW APPLICATION ENTERED
Oct 25, 2021 NWAP